Agomab Therapeutics NV (AGMB)
Market Open
12 Jun, 13:55
NASDAQ (NMS) NASDAQ (NMS) Primary $
9. 78
-0.1
-0.9706%
$
488.54M Market Cap
- P/E Ratio
- Div Yield
8,946 Volume
- Eps
$ 9.88
Previous Close Investors:
Want to track AGMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AgomAb Therapeutics: High Risk, High Reward Stock
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drugs targeting large addressable markets. AGMB-129 (Crohn's disease) and AGMB-447 (IPF) have Fast Track and Orphan Drug designations, indicating significant unmet need and regulatory advantages. Strong backing from major pharma players and a high institutional ownership position, AGOM is a potential acquisition target upon successful trial outcomes.
Seekingalpha | 1 week ago
